Grand Pharmaceutical Group's Ophthalmic Product Gets Drug Approval in China

MT Newswires Live
17 Dec 2024

Grand Pharmaceutical Group (HKG:0512) said its innovative ophthalmic product GPN01768's new drug application (NDA) was recently accepted by China's National Medical Products Administration (NMPA), according to a Monday filing with the Hong Kong bourse.

The medication is used for the treatment of Demodex blepharitis, which is caused by Demodex mites.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10